EUCTR2005-002692-33-BE进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension - LVGY
illy ICOS LLC0 个研究点目标入组 400 人开始时间: 2005年10月26日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-=12 years of age.
- •-Body weight = 40 kg.
- •-Currently have a diagnosis of PAH that is either:
- •oidiopathic,
- •orelated to collagen vascular disease,
- •orelated to anorexigen use,
- •oassociated with an atrial septal defect (with resting arterial oxygen saturation = 88% on room air at screening), or
- •owith surgical repair, of at least 1 yr duration, of a congenital systemic-to-pulmonary shunt (e.g., ventricular septal defect, patent ductus arteriosus).
- •-Have a history of the diagnosis of PAH established by a resting mean pulmonary artery pressure =25 mm Hg, pulmonary artery wedge pressure =15 mm Hg, and a pulmonary vascular resistance (PVR) = 3 Wood units via right heart catheterization.
- •-If on bosentan, must be at the maximal dose of 125 mg twice daily for a minimum of 12 weeks prior to screening and have a screening AST/ALT < 3 times upper limit of normal.
- •-Have a chest radiograph (CXR) within 6 months of screening that shows clear lung fields or no more than mild patchy (not diffuse) interstitial infiltrates.
- •-Have no evidence of significant parenchymal lung disease, as evidenced by pulmonary function tests within 6 months of screening showing total lung capacity = 60% predicted.
- •-Have a 6-minute walk test distance =150 and =450 meters at screening.
- •-Have World Health Organization (WHO) functional class I, II, III or IV status.
- •-A female subject of childbearing potential must have a negative serum pregnancy test at the screening visit and agree to use two medically reliable methods of contraception (e.g., barrier with either spermacide or hormonal contraception) until study completion.
- •-Written informed consent (and written assent for minors) will be obtained prior to any study procedure being performed.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Are nursing or pregnant.
- •-Have pulmonary hypertension related to conditions other than specified above, including but not limited to chronic thromboembolic disease, portal pulmonary hypertension, HIV infection, or left heart disease.
- •-For subjects with pulmonary arterial hypertension associated with an atrial septal defect, resting arterial oxygen saturation (SaO2) < 88% on room air at screening.
- •-History of left-sided heart disease, including any of the following:
- •·clinically significant aortic or mitral valve disease (i.e., aortic stenosis, aortic insufficiency, mitral stenosis, moderate or greater mitral regurgitation);
- •·pericardial constriction;
- •·restrictive or congestive cardiomyopathy;
- •·left ventricular ejection fraction < 40% by multigated radionucleotide angiogram (MUGA), angiography, or echocardiography;
- •·left ventricular shortening fraction < 22% by echocardiography;
- •·life-threatening cardiac arrhythmias.
- •-History of atrial septostomy within 3 months before administration of study drug.
- •-Have severe hepatic impairment, Child-Pugh Class C (see Appendix C).
- •-Have severe renal insufficiency, defined as receiving renal dialysis or having a measured or estimated creatinine clearance (CC) < 30 mL/min (Cockroft-Gault formula, below) at screening:
- •CC = [(140 – age) x weight (kg)/ serum creatinine (mg/dL) ´ 72] ´ 0.85 (female) or 1.00 (male)
- •-Have a systolic blood pressure >160 mm Hg or < 90 mm Hg, or diastolic blood pressure >100 mm Hg or < 50 mm Hg at screening.
- •-Have a history of angina pectoris or other condition that was treated with long-or short-acting nitrates within 12 weeks before administration of study drug.
- •-Have a musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease besides pulmonary hypertension that may significantly limit ambulation.
- •-Have a history of symptomatic coronary disease.
- •-Have a history of HIV infection.
- •-Have any new long-term treatment for pulmonary arterial hypertension added within 4 weeks before administration of study drug.
- •-Have any therapy with a prostacyclin or analogue, L-arginine, phosphodiesterase inhibitor, or investigational drug within 4 weeks before administration of study drug.
- •-Have any chronic PAH medication except for anticoagulants discontinued within 4 weeks prior to administration of study drug.
- •-Current treatment with antiretroviral therapy (protease inhibitor), ketoconazole, or itraconazole.
- •-Are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
- •-Are employed by Lilly or ICOS (that is, employees, temporary contract workers, or designees responsible for the conduct of the study). Immediate family of Lilly or ICOS employees may participate in Lilly ICOS LLC-sponsored clinical trials, but are not permitted to participate at a Lilly or ICOS facility. Immediate family is defined as a spouse, parent, child, or sibling, whether biological or legally adopted.
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Phosphodiesterase Type 5 (PDE5) Inhibitor Tadalafil in the Treatment of Patients with Pulmonary Arterial Hypertension - LVGYEUCTR2005-002692-33-DEilly ICOS LLC400
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Investigate the Efficacy and Safety of Progesterone in Patients with Severe Traumatic Brain Injury - NDSevere brain injuryMedDRA version: 9.1Level: LLTClassification code 10060690EUCTR2010-018283-16-ITBHR PHARMA, LLC1,180
进行中（未招募）
1 期
A Phase 2a Study to Evaluate the Efficacy and Safety of Tildrakizumab in Patients with Active Ankylosing Spondylitis or Non-Radiographic Axial SpondyloarthritisAnkylosing spondylitis (AS) and Non-Radiographic Axial Spondyloarthritis (nr-axSpA)EUCTR2016-003936-19-HUSUN Pharmaceuticals Global FZE180
进行中（未招募）
不适用
The study is designed to determine the safety and efficacy of Progesterone in patients with severe head injurySevere traumatic brain injuryMedDRA version: 17.0Level: LLTClassification code 10060690Term: Traumatic brain injurySystem Organ Class: 100000004863EUCTR2010-018283-16-FIBHR Pharma, LLC1,180
进行中（未招募）
1 期
Study to evaluate the efficacy of IPI-145 administered in combination with rituximab vs placebo in combination with rituximab in subjects with previously treated CD20-positive FFollicular LymphomaEUCTR2013-002406-31-PLInfinity Pharmaceuticals, Inc400